TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    SPY (-1.93%)    AMZN (-3%)    VXXB (11.47%)    LVS (-2.67%)    MCD (0.24%)    NFLX (-4.47%)    NRG (-2.03%)    NXST (-3.18%)    PBR (-7.22%)    PEI (0.33%)    POST (-0.17%)    PYPL (-2.77%)    QQQ (-2.2%)    ROKU (-4.53%)    SBUX (-0.42%)    SCIF (-3.28%)    SLNO (2.35%)    WYNN (-3.5%)    XLE (-2.71%)    XLF (-2.77%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    SQ (-4.39%)

 TGTX - TG Therapeutics

$6.83 [-0.56][-7.58%]

Next Earnings



Trade Idea »


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



What Makes TG Therapeutics (TGTX) a New Strong Buy Stock

TG Therapeutics TGTX appears an attractive pick as it has been recently upgraded to a Zacks Rank 1 Strong Buy This upgrade is essentially a reflection of an upward trend in earnings estimates one of the most powerful forces impacting stock prices The sole determinant of the Zacks

This Is Why TG Therapeutics Stock Soared 65.9% in February

What happened Fueled by trial data TG Therapeutics NASDAQ TGTX 160 shares skyrocketed 69 5 in February according to S amp P Global Market Intelligence So what On Jan 30 data from phase 1 trials evaluating TG Therapeutics ublituximab and

The Meet Group (MEET) to Report Q4 Earnings: What's in Store?

The Meet Group MEET is set to release fourth quarter 2018 results on Mar 6 In the las t report ed quarter The Meet Group s earnings of 10 cents per share beat the Zacks Consensus Estimate by a penny However the figure declined 9 1 year over year Revenues of 45 7 million surged

Why These Pharma ETFs Rallied on Thursday

Pharma ETFs have seen solid trading on Feb 28 as positive drug data and events in the cannabis industry were cheered by investors Despite the ongoing controversy related to high drug prices fundamentals appear to be strong for the space The merger and acquisition backdrop has also been solid

Why TG Therapeutics Stock Skyrocketed 30.5% Today

What happened After reporting positive data from one cohort of a trial evaluating its lymphoma drug umbralisib TG Therapeutics NASDAQ TGTX 160 shares soared 30 5 as of 3 35 p m EST So what Marginal zone lymphoma MZL is typically diagnosed in elderly

Health Care Sector Update for 02/28/2019: TGTX, NVAX, RKDA

Top Health Care StocksTop Health Care Stocks JNJ 0 9 JNJ 0 9 PFE 1 1 PFE 1 1 MRK 0 8 MRK 0 8 ABT 0 6 ABT 0 6 AMGN 0 6 AMGN 0 6 Health care stocks were mostly firmer as Thursday s regular session ended with the NYSE Health Care Index gaining 0 3 late this afternoon

Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?

DENTSPLY SIRONA Inc s XRAY fourth quarter 2018 results are expected to be released very soon The company s focus on Research and Development R amp D is expected to boost quarterly results Let s take a look at other major factors that will influence DENTSPLY SIRONA s performance in